Reawaken the GH pulse before layering local growth signals.
By your mid-30s, the pituitary still has the machinery to fire growth hormone in the deep, undulating waves it produced at 25 — it just stops doing it. Pulse amplitude collapses, nighttime release flattens, and IGF-1 drifts down with it. Before you bolt local growth signals (BPC-157, TB-500, IGF-1 LR3) onto a recomposition stack, you rebuild the systemic anabolic backdrop. That's what Weeks 1–4 are for. You are not chasing a supraphysiologic GH bolus. You are restoring the natural pulsatile pattern your pituitary used to run on its own.
This is the foundation phase. Get it wrong and every compound you stack on top fires into a dead signaling environment.
What's actually happening at the cellular level
Growth hormone is not released as a flat ribbon. The hypothalamus pulses GHRH in undulating waves — strongest at night during deep sleep, sharpest in response to fasting and metabolic stress. The pituitary somatotrophs respond by releasing GH in bursts. The liver reads those bursts and converts the signal into IGF-1, which is the actual mitogen reaching muscle, tendon, and connective tissue.
CJC-1295 and Ipamorelin attack this circuit from two different angles, and that is why the stack is the gold standard rather than either compound alone.
CJC-1295 (with DAC) is a GHRH analogue with a Drug Affinity Complex that extends its half-life past 8 days. One weekly subcutaneous injection produces a sustained elevation in baseline GHRH tone — not a spike, a steady underlying signal. The pituitary stays primed. Practitioner consensus frames this as the "baseline" lever: it raises the floor, not the ceiling.
Ipamorelin is a selective ghrelin-receptor agonist. It triggers a sharp, brief GH pulse — "smashing the pedal to the floor and turning the key off," as the practitioner corpus describes it — and then it's gone. Critically, it does not spill into cortisol or prolactin release, which is what separates it from older GHRPs like Hexarelin or GHRP-6. The pulse is clean.
Run together, the two compounds produce something neither does alone: a sustained baseline of GHRH tone (CJC-1295) on top of which Ipamorelin's pulses ride higher. The practitioner corpus describes this as the "synergistic" GH stack — sustained baseline plus sharp pulses, combining for total daily output that mimics a younger pituitary's natural rhythm. Because the body still self-regulates via somatostatin feedback, this is fundamentally different from injecting recombinant HGH — which delivers a flat unnatural bolus, suppresses your own production, and carries water retention, joint pain, and insulin-resistance side effects this protocol largely sidesteps.
The IGF-1 elevation is your measurable proxy. Expect it to climb at 4–6 weeks — not Week 1. The pituitary needs time to re-learn the rhythm.
Protocol prescription — Phase 1 stack
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| CJC-1295 (with DAC) | 2 mg per week | Subcutaneous, abdomen-near | Once weekly, any time of day | 🟢 Expert | 8+ day half-life makes timing flexible. Pick a fixed day (e.g. Sunday night) and stick to it. |
| Ipamorelin | 100–200 mcg | Subcutaneous, abdomen-near | 2× daily — morning fasted + pre-bed | 🟢 Expert | The pre-bed dose stacks with your natural sleep-time GH surge. The morning dose extends pulsatile output across the day. |
| Ipamorelin (alt single-dose protocol) | 200–300 mcg | Subcutaneous | 1× daily, pre-bed fasted | 🟢 Expert | Use this if twice-daily compliance is unrealistic. The corpus cites 200–300 mcg pre-bed as the most-used real-world dose. |
Non-negotiables — timing rules:
- Fasted. Food within 30 minutes of injection — especially carbs and fat — blunts the GH pulse by 50–80%. Wait 20–30 minutes after injection before eating. The pre-bed dose means last meal ends 2+ hours before injection.
- Empty stomach in the morning. If you train fasted, inject Ipamorelin on waking, train, then eat.
- Site rotation. Subcutaneous, into abdominal fat 1–2 inches from the navel. Rotate sites in a clock pattern across the 28 days to avoid lipoatrophy and scar tissue.
- Do not stack with progesterone cream at the same time. The corpus is explicit: progesterone cream blunts GH secretagogue effects. Separate administration by at least 4–6 hours.
Hard contraindication before you start: If fasting insulin is above 8 mIU/L, do not run this stack. Growth hormone antagonizes insulin. Pushing GH secretagogues into an already insulin-resistant system worsens the resistance and accelerates the metabolic problem you're trying to solve. Fix insulin first — that's a different Path. Pull baseline bloodwork: IGF-1, fasting insulin, fasting glucose, HbA1c. Without these numbers you are flying blind.
What you should feel
Week 1:
- Deeper sleep onset within 3–5 nights of starting Ipamorelin pre-bed. Slow-wave sleep is the first thing GH pulses restore.
- Mild flushing or a faint head-warming sensation in the first 5–10 minutes post-injection. Normal. Fades.
- Possible mild hunger uptick from the ghrelin-receptor pathway. Manageable; not the appetite spike you get from GHRP-6 or MK-677.
Week 2:
- More vivid dreams. REM architecture deepening.
- Subjective recovery improving — DOMS clears faster between training sessions.
Week 3–4:
- Skin quality begins to shift. Practitioner consensus calls this one of the earliest visible markers.
- Morning energy more stable. Less of the 3pm crash if cortisol rhythm is intact.
- IGF-1 measurable on bloodwork — pull labs end of Week 4. Expect movement, not a doubling.
What's NOT happening yet
- Visible body composition changes. Four weeks of restored GH pulsatility does not rebuild muscle architecture. That's Phase 2's job, when local growth signals layer on top of this systemic backdrop.
- Dramatic strength gains. GH is permissive for hypertrophy via IGF-1; it is not directly anabolic at the muscle fiber the way testosterone or IGF-1 LR3 is. Strength PRs are not the Week 4 metric.
- Fat loss as a primary effect. Some lipolysis from elevated GH baseline, yes — but body recomposition is a Phase 2+ outcome, not a foundation-phase deliverable. Anyone promising you a visual transformation in 28 days from CJC + Ipamorelin alone is selling you the wrong story.
- A "feeling" on injection day. Unlike testosterone or a stim, you will not feel the dose. The pulses happen during sleep. The signal is downstream. Resist the urge to chase a sensation by doubling the dose — that drives toward water retention, numbness, and pituitary desensitization. Less is more in this circuit.
- Insulin resistance, if you respected the entry criteria. If fasting glucose creeps up by Week 4, that's a red flag — pull insulin and HbA1c and reassess before Phase 2.
The point of Phase 1 is not to feel transformed. The point is to rebuild the signaling environment so that Phase 2's local repair and growth compounds (BPC-157, TB-500, IGF-1 LR3) fire into a primed system instead of a flatlined one. The muscle building happens later. The foundation happens now.
Research describes this. Track IGF-1 and fasting insulin. Adjust.